Hygeia Pharmaceuticals Inc. has received a $50,000 Phase Ismall business innovation research (SBIR) grant from theNational Cancer Institute for research on the generation ofbetter fusion partners for the preparation of humanmonoclonal antibodies.

A subsidiary of San Diego-based Hygeia Holdings Inc., thecompany is focused on cancer therapeutics.

(c) 1997 American Health Consultants. All rights reserved.